PREFERENCES FOR ROUTE OF ADMINISTRATION, FREQUENCY AND LOCATION - A TIME-TRADE-OFF STUDY IN THE ITALIAN GENERAL POPULATION
Author(s)
Jørgensen T1, Franchi A2, Lelli F3, Lee XY1, Bøgelund M4, Alulis S1
1Janssen-Cilag Denmark, Birkerød, Denmark, 2Janssen-Cilag SpA, Cologno Monzese, Italy, 3Recordati S.p.A, Milan, Italy, 4Incentive, Holte, Denmark
OBJECTIVES: The objective of this study was to investigate preferences from the Italian general population for route, frequency and location of treatment administration, independent of disease area. METHODS: We developed eight health states varying the route of administration (subcutaneous injection/intravenous infusion), frequency (every 1/2/4/8/12 weeks), and location (hospital/home) to correspond with treatment regimens for a number of commonly used biologic compounds. The time-trade-off (TTO) method was applied to elicit utility values associated with each health state. Respondents were repeatedly asked to ‘trade off’ a portion of their remaining lifespan for perfect health until a point of indifference was found. 1,547 respondents (≥ 18 years old) from the Italian general population who were recruited through a representative internet-based survey panel completed the questionnaire. A utility value was assigned to each health state based on each individual’s response, derived from the midpoint of the indifference interval. RESULTS: Respondents preferred less frequent administration both for subcutaneous injections (weekly subcutaneous injections at home: 0.859; bi-weekly: 0.859; 8-weekly: 0.871; 12-weekly: 0.874) and infusions (infusions at the hospital 4-weekly: 0.831; 8-weekly: 0.838). Additionally, respondents prefer a subcutaneous injection at home rather than at the hospital (subcutaneous injections every 12 weeks at the hospital: 0.870; at home: 0.874) and subcutaneous injection to infusion (treatment every 8 weeks at the hospital, infusion: 0.838; subcutaneous injection: 0.856). Receiving a subcutaneous injection at home every 12 weeks was preferred over all other health states (however not significantly for subcutaneous injection at home every 4/8 weeks). CONCLUSIONS: Route, frequency and location of administration matter for members of the general public as they have an impact on convenience. The best combination of administration and frequency is receiving a subcutaneous injection every 12 weeks at home, showing that more convenient treatment regimens are associated with higher utility values.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PGI35
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Gastrointestinal Disorders